![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Roche’s Tecentriq Gains NICE Recommendation After Prior Rejection
Roche’s Tecentriq Gains NICE Recommendation After Prior Rejection
![NICE-logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/NICE-logo.gif?t=1604717099&width=430)
April 10, 2018
The U.K.’s National Institute for Health and Care Excellence (NICE), which previously shot down Roche’s immunotherapy Tecentriq (atezolizumab) for use in treating non-small cell lung cancer (NSCLC), reversed its decision, offering its recommendation for patients whose disease progressed following standard chemotherapy.
NICE’s reversal was based on Roche’s data from a Phase 3 study showing that patients with advanced NSCLC lived 4.2 months longer than those who received standard chemotherapy and experienced fewer side effects.
Tecentriq is a monoclonal antibody that binds with a protein, PD-L1, and stops it from camouflaging cancer cells to avoid detection and removal by the immune system.
Upcoming Events
-
21Oct